Navigation Links
CET Life Sciences Center Welcomes Belmont University School of Pharmacy as New Tenant
Date:7/1/2008

oviding laboratory and equipment infrastructure to support their promising research."

Belmont's School of Pharmacy announced last week that it has received approval from The Accreditation Council for Pharmacy Education (ACPE) to seat its first class of 75 students for the 2008-09 academic year.

Belmont University, host of the 2008 Town Hall Presidential Debate, is a fast-growing community of nearly 4,800 students who come from almost every state and more than 25 countries. Committed to being a leader among teaching universities, Belmont brings together the best of liberal arts and professional education in a Christian community of learning and service. Belmont's purpose is to help students explore their passions and develop their talents to meet the world's needs. With more than 75 areas of study, 12 master's programs and three doctoral degrees, there is no limit to the ways Belmont University can expand an individual's horizon. For more information, visit http://www.belmont.edu.

Cumberland Emerging Technologies, Inc. (http://www.cet-fund.com) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University and the Tennessee Technology Development Corporation. The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace. CET helps manage the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure to early-stage life sciences companies.


'/>"/>
SOURCE Cumberland Emerging Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
11. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... MN (PRWEB) , ... July 31, 2015 , ... Ralco ... Enrichment Center at the Lyon County Fair to be held August 5-9 in Marshall. ... about where their meals come from and how agriculture impacts their daily lives. This ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... , July 30, 2015 Ascendis Pharma ... that applies its innovative TransCon technology to address ... results from a six-month Phase 2 study to ... Growth Hormone in 53 treatment-naïve, pre-pubertal children with ... are extremely pleased with the top-line results from ...
(Date:7/29/2015)... , July 30, 2015 ... results for the second quarter of 2015. CEO ... results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered ... results - Performance drivers ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Focus on ... Supportive ... Companies, Inc. (NYSE: PRX ) today announced its commitment,to ... of Strativa Pharmaceuticals, its proprietary,specialty pharmaceuticals division. Strativa Pharmaceuticals will ...
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ), a ... of drugs for the treatment of human ... part of the,restructuring, Idenix has amended the ... Tyzeka(R)/Sebivo(R). Per the amended agreement, Idenix,will discontinue ...
... Settlement, NORCROSS, Ga., Sept. 28 ... leader in providing automated instrument-reagent,systems to the ... and Exchange Commission (SEC) has agreed to ... certain,activities involving the company,s Italian subsidiary. ...
Cached Biology Technology:Introducing Strativa Pharmaceuticals 2Introducing Strativa Pharmaceuticals 3Introducing Strativa Pharmaceuticals 4Introducing Strativa Pharmaceuticals 5Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 2Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 3Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 4Immucor Settles SEC Investigation 2
(Date:7/13/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... method to make payments.  With this patent, NXT-ID ... its groundbreaking voice-direct payment patent application, with behavior-directed ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... frequently exposed to heavy traffic pollution or smoke from wood ... University of Melbourne led study has found. The study ... of traffic pollution and wood smoke from heaters on middle-aged ... suffer asthma and were exposed to heavy traffic pollution experienced ...
... needs iron to establish and maintain a biofilm in ... proposed to deprive the bacteria of this necessary element. However, ... published in mBio , the online open-access journal of ... of the two types of iron that are available in ...
... to thousands of species of bacteria collectively called the ... existence. The gastrointestinal (GI) tractand the colon in particularis ... bacterial species. But how do these organisms persist and ... due to foods and fluids moving through it? A ...
Cached Biology News:Traffic pollution and wood smoke increases asthma in adults 2Target 2 forms of iron to control cystic fibrosis lung infection 2A home for the microbiome 2A home for the microbiome 3A home for the microbiome 4
albumin from bovine serum (BSA), tetramethylrhodamine conjugate...
... VIP (6-28) (human, bovine, porcine, ... Peptide (VIP) receptor antagonist. This ... to be twofold more potent ... receptor antagonists. ...
... Invitrogens EvoQuest Services are uniquely ... in the current competitive environment. ... techniques to express, purify, and ... needs: Structure/Function Studies, Activity Assays, ...
Request Info...
Biology Products: